Dr. Ribas is professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He serves as director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and director of the Parker Institute for Cancer Immunotherapy Center at UCLA. His research has focused on the use of immunotherapy to treat melanoma. Dr. Ribas led the clinical program that demonstrated the effectiveness of the immunotherapeutic pembrolizumab (Keytruda), which has been a significant advancement in the treatment of melanoma. He is an elected member of the Royal Academy of Medicine of Catalonia and the American Society of Clinical Investigation, and also the 2019-2020 president-elect of the AACR.